Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Interest Expenses (2022 - 2025)

Historic Interest Expenses for TScan Therapeutics (TCRX) over the last 4 years, with Q3 2025 value amounting to $699000.0.

  • TScan Therapeutics' Interest Expenses fell 2703.55% to $699000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year decrease of 2338.08%. This contributed to the annual value of $3.7 million for FY2024, which is 281.99% down from last year.
  • TScan Therapeutics' Interest Expenses amounted to $699000.0 in Q3 2025, which was down 2703.55% from $689000.0 recorded in Q2 2025.
  • Over the past 5 years, TScan Therapeutics' Interest Expenses peaked at $982000.0 during Q3 2023, and registered a low of $201000.0 during Q3 2022.
  • For the 4-year period, TScan Therapeutics' Interest Expenses averaged around $819615.4, with its median value being $952000.0 (2024).
  • As far as peak fluctuations go, TScan Therapeutics' Interest Expenses skyrocketed by 38855.72% in 2023, and later tumbled by 2919.71% in 2025.
  • Over the past 4 years, TScan Therapeutics' Interest Expenses (Quarter) stood at $975000.0 in 2022, then dropped by 12.62% to $852000.0 in 2023, then fell by 7.98% to $784000.0 in 2024, then fell by 10.84% to $699000.0 in 2025.
  • Its Interest Expenses was $699000.0 in Q3 2025, compared to $689000.0 in Q2 2025 and $679000.0 in Q1 2025.